REPORT ID 5219

EMEA (Europe, Middle East and Africa) Somatostatin Receptor Type 2 Market Report 2017

Publish Date
20-Dec-17
Pages
109
Format
Electronic (PDF)

In this report, the EMEA Somatostatin Receptor Type 2 market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Somatostatin Receptor Type 2 for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Somatostatin Receptor Type 2 market competition by top manufacturers/players, with Somatostatin Receptor Type 2 sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Amryt Pharma plc
    Crinetics Pharmaceuticals Inc
    Daewoong Pharmaceutical Co Ltd
    Ipsen SA
    Progenics Pharmaceuticals Inc
    Strongbridge Biopharma plc
    Zucara Therapeutics Inc
    ...

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    CRN-00808
    Lanreotide Acetate
    PRL-2903
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hormonal Disorder
    Oncology
    Metabolic Disorder
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Somatostatin Receptor Type 2 Market Report 2017
1 Somatostatin Receptor Type 2 Overview
    1.1 Product Overview and Scope of Somatostatin Receptor Type 2
    1.2 Classification of Somatostatin Receptor Type 2
        1.2.1 EMEA Somatostatin Receptor Type 2 Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Somatostatin Receptor Type 2 Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 CRN-00808
        1.2.4 Lanreotide Acetate
        1.2.5 PRL-2903
        1.2.6 Others
    1.3 EMEA Somatostatin Receptor Type 2 Market by Application/End Users
        1.3.1 EMEA Somatostatin Receptor Type 2 Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hormonal Disorder
        1.3.3 Oncology
        1.3.4 Metabolic Disorder
        1.3.5 Others
    1.4 EMEA Somatostatin Receptor Type 2 Market by Region
        1.4.1 EMEA Somatostatin Receptor Type 2 Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Somatostatin Receptor Type 2 (2012-2022)
        1.5.1 EMEA Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Somatostatin Receptor Type 2 Revenue and Growth Rate (2012-2022)

2 EMEA Somatostatin Receptor Type 2 Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Somatostatin Receptor Type 2 Market Competition by Players/Manufacturers
        2.1.1 EMEA Somatostatin Receptor Type 2 Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Somatostatin Receptor Type 2 Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Somatostatin Receptor Type 2 Sale Price by Players (2012-2017)
    2.2 EMEA Somatostatin Receptor Type 2 (Volume and Value) by Type/Product Category
        2.2.1 EMEA Somatostatin Receptor Type 2 Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Somatostatin Receptor Type 2 Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Somatostatin Receptor Type 2 Sale Price by Type (2012-2017)
    2.3 EMEA Somatostatin Receptor Type 2 (Volume) by Application
    2.4 EMEA Somatostatin Receptor Type 2 (Volume and Value) by Region
        2.4.1 EMEA Somatostatin Receptor Type 2 Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Somatostatin Receptor Type 2 Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Somatostatin Receptor Type 2 Sales Price by Region (2012-2017)

3 Europe Somatostatin Receptor Type 2 (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Somatostatin Receptor Type 2 Sales and Value (2012-2017)
        3.1.1 Europe Somatostatin Receptor Type 2 Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Somatostatin Receptor Type 2 Revenue and Growth Rate (2012-2017)
    3.2 Europe Somatostatin Receptor Type 2 Sales and Market Share by Type
    3.3 Europe Somatostatin Receptor Type 2 Sales and Market Share by Application
    3.4 Europe Somatostatin Receptor Type 2 Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Somatostatin Receptor Type 2 Sales Volume by Countries (2012-2017)
        3.4.2 Europe Somatostatin Receptor Type 2 Revenue by Countries (2012-2017)
        3.4.3 Germany Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        3.4.4 France Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        3.4.5 UK Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        3.4.6 Russia Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        3.4.7 Italy Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)

4 Middle East Somatostatin Receptor Type 2 (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Somatostatin Receptor Type 2 Sales and Value (2012-2017)
        4.1.1 Middle East Somatostatin Receptor Type 2 Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Somatostatin Receptor Type 2 Revenue and Growth Rate (2012-2017)
    4.2 Middle East Somatostatin Receptor Type 2 Sales and Market Share by Type
    4.3 Middle East Somatostatin Receptor Type 2 Sales and Market Share by Application
    4.4 Middle East Somatostatin Receptor Type 2 Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Somatostatin Receptor Type 2 Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Somatostatin Receptor Type 2 Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        4.4.4 Israel Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        4.4.5 UAE Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        4.4.6 Iran Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)

5 Africa Somatostatin Receptor Type 2 (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Somatostatin Receptor Type 2 Sales and Value (2012-2017)
        5.1.1 Africa Somatostatin Receptor Type 2 Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Somatostatin Receptor Type 2 Revenue and Growth Rate (2012-2017)
    5.2 Africa Somatostatin Receptor Type 2 Sales and Market Share by Type
    5.3 Africa Somatostatin Receptor Type 2 Sales and Market Share by Application
    5.4 Africa Somatostatin Receptor Type 2 Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Somatostatin Receptor Type 2 Sales Volume by Countries (2012-2017)
        5.4.2 Africa Somatostatin Receptor Type 2 Revenue by Countries (2012-2017)
        5.4.3 South Africa Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Somatostatin Receptor Type 2 Sales and Growth Rate (2012-2017)

6 EMEA Somatostatin Receptor Type 2 Manufacturers/Players Profiles and Sales Data
    6.1 Amryt Pharma plc
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Somatostatin Receptor Type 2 Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Amryt Pharma plc Somatostatin Receptor Type 2 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Crinetics Pharmaceuticals Inc
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Somatostatin Receptor Type 2 Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Crinetics Pharmaceuticals Inc Somatostatin Receptor Type 2 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Daewoong Pharmaceutical Co Ltd
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Somatostatin Receptor Type 2 Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Daewoong Pharmaceutical Co Ltd Somatostatin Receptor Type 2 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Ipsen SA
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Somatostatin Receptor Type 2 Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Ipsen SA Somatostatin Receptor Type 2 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Progenics Pharmaceuticals Inc
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Somatostatin Receptor Type 2 Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Progenics Pharmaceuticals Inc Somatostatin Receptor Type 2 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Strongbridge Biopharma plc
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Somatostatin Receptor Type 2 Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Strongbridge Biopharma plc Somatostatin Receptor Type 2 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Zucara Therapeutics Inc
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Somatostatin Receptor Type 2 Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Zucara Therapeutics Inc Somatostatin Receptor Type 2 Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    ...

7 Somatostatin Receptor Type 2 Manufacturing Cost Analysis
    7.1 Somatostatin Receptor Type 2 Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Somatostatin Receptor Type 2

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Somatostatin Receptor Type 2 Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Somatostatin Receptor Type 2 Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Somatostatin Receptor Type 2 Market Forecast (2017-2022)
    11.1 EMEA Somatostatin Receptor Type 2 Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Somatostatin Receptor Type 2 Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Somatostatin Receptor Type 2 Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Somatostatin Receptor Type 2 Price and Trend Forecast (2017-2022)
    11.2 EMEA Somatostatin Receptor Type 2 Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Somatostatin Receptor Type 2 Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Somatostatin Receptor Type 2 Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Somatostatin Receptor Type 2 Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Somatostatin Receptor Type 2 Sales Forecast by Type (2017-2022)
    11.7 EMEA Somatostatin Receptor Type 2 Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer